Print Page | Sign In | Join Today
News & Press: VABIO News

VABIO Chairman Mike Grisham on BioCentury This Week

Monday, September 16, 2013  
Share |
Two constants are death and taxes. But in many R&D industries, startups face death before taxes.Unless investors are willing to finance years of losses, technologies that could transform health and society die on the vine.Now biotech and other members of the Coalition of Small Business Innovators want to relax provisions of the U.S. tax code they say are keeping capital at bay.The accounting firm Ernst & Young estimates the proposed changes could spur $20 billion of investment and create more than 600,000 jobs.But is it doable? The September 15 edition of BioCentury This Week television digs into the details with:
  • Christopher Ohmes, Partner at Ernst & Young
  • Jeffrey Hatfield, President & CEO of Vitae Pharmaceuticals and member of the Board of Directors at the Biotechnology Industry Organization
  • Michael Grisham, Founder & CEO of GPB Scientific and the Chair of Virginia Bio


BioCentury 09.15.13 - [1] Two Constants

Our Premium Partners

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected